Compare CFG & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFG | UTHR |
|---|---|---|
| Founded | 1828 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.5B | 20.3B |
| IPO Year | 2014 | 1999 |
| Metric | CFG | UTHR |
|---|---|---|
| Price | $55.74 | $483.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 12 |
| Target Price | $55.83 | ★ $495.08 |
| AVG Volume (30 Days) | ★ 3.9M | 412.1K |
| Earning Date | 01-16-2026 | 10-29-2025 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 41.06 | 16.08 |
| EPS | 3.57 | ★ 26.38 |
| Revenue | ★ $7,443,000,000.00 | $3,128,400,000.00 |
| Revenue This Year | $17.05 | $13.68 |
| Revenue Next Year | $8.73 | $5.63 |
| P/E Ratio | ★ $15.65 | $18.40 |
| Revenue Growth | 4.61 | ★ 13.50 |
| 52 Week Low | $32.60 | $266.98 |
| 52 Week High | $56.05 | $492.62 |
| Indicator | CFG | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 67.74 | 65.15 |
| Support Level | $53.78 | $470.13 |
| Resistance Level | $54.64 | $486.46 |
| Average True Range (ATR) | 1.21 | 10.39 |
| MACD | 0.39 | -0.88 |
| Stochastic Oscillator | 93.72 | 70.12 |
Citizens Financial Group Inc is a bank holding company headquartered in Providence, Rhode Island. Through the bank, it offers various retail and commercial banking products and services to individuals, small businesses, middle-market companies, large corporations, and institutions. The company's reportable segments are; Commercial Banking, Consumer Banking, Non-Core, and Others. A majority of its revenue is generated from the Consumer Banking segment, which serves consumer customers and small businesses, offering traditional banking products and services including deposits, mortgage and home equity lending, credit cards, small business loans, education loans, point-of-sale finance loans, and wealth management and investment services.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.